DISEASE CHARACTERISTICS:

• Histologically confirmed advanced solid tumor for which no curative therapy exists

  • Non-Hodgkin's lymphoma allowed
• No leukemia
• No active CNS involvement with tumor

PATIENT CHARACTERISTICS:

Age:

• 19 and over

Performance status:

• ECOG 0-2

Life expectancy:

• At least 3 months

Hematopoietic:

• Absolute neutrophil count at least 2,000/mm^3
• Platelet count at least 100,000/mm^3

Hepatic:

• Bilirubin ≤ upper limit of normal (ULN)
• AST no greater than 2 times ULN (no greater than 98 U/L)

Renal:

• Creatinine ≤ ULN OR
• Creatinine clearance at least 60 mL/min

Cardiovascular

• None of the following significant cardiac diseases:

  • New York Heart Association class III or IV heart failure
  • History of myocardial infarction within the past year
  • Uncontrolled dysrhythmias
  • Poorly controlled angina
• No serious ventricular arrhythmia (i.e., ventricular tachycardia (VT) or ventricular fibrillation (VF) ≥ 3 beats in a row)
• QTc interval ≤ 450 msec for men or ≤ 470 msec for women
• LVEF ≥ 40% by MUGA

Other:

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No other serious medical condition that would preclude study participation
• No serious hypersensitivity to egg products

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No concurrent anticancer immunotherapy

Chemotherapy:

• At least 4 weeks since prior chemotherapy and recovered
• No other concurrent anticancer chemotherapy (e.g., cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] or mechlorethamine, vincristine, procarbazine, and prednisone [MOPP])

Endocrine therapy:

• No concurrent anticancer hormonal therapy

• No concurrent anticancer glucocorticoids

  • Concurrent glucocorticoids as antiemetics for nonmalignant disease allowed

Radiotherapy:

• At least 4 weeks since prior radiotherapy and recovered
• No concurrent radiotherapy

Surgery:

• No concurrent major surgery

Other:

• No concurrent drugs that interfere with hepatic CYP3A4 metabolism (e.g., grapefruit juice, ketoconazole, fluconazole, itraconazole, cyclosporine, erythromycin, clarithromycin, cimetidine, terfenadine, astemizole, indinavir, or nelfinavir mesylate)
• No concurrent medications that cause QTc prolongation